News Formal

Companies Continue to Invest in Carbon Capture and Storage Technology

  • 📰 OilandEnergy
  • ⏱ Reading Time:
  • 15 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 37%
  • Publisher: 68%

Technology News

Carbon Capture And Storage,CCS,Decarbonisation

Despite skepticism from experts, companies worldwide are heavily investing in carbon capture and storage (CCS) technology as a means of reducing carbon emissions. However, environmentalists and scientists have concerns about the effectiveness and overhyping of CCS. Private companies and state governments are still investing in CCS to meet climate targets, although its success on a large scale remains uncertain.

While experts are sceptical about carbon capture and storage (CCS) technology, companies worldwide are still investing heavily in it as a means of decarbonisation. CCS is seen as a way for oil and gas firms to decrease their carbon emissions while continuing to pump oil. However, environmentalists criticize CCS as a band-aid solution, and scientists believe it is being overhyped with few proven results.

Despite this, private companies and state governments are investing in CCS to meet climate targets. The success of CCS technologies on a large scale is uncertain due to complexity and cost. Only companies in hard-to-abate industries are currently investing in CCS equipment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 34. in BUSİNESS
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Study suggests pharmaceutical companies unfairly maintain high insulin costs through patenting processesA new study reveals that pharmaceutical companies have been using patenting processes to unfairly maintain high insulin costs, adding to the financial burden faced by patients and insurers. The study highlights the role of the FDA's Orange Book and the U.S. Patent and Trademark Office in governing patent ownership and market competition.
Source: TIME - 🏆 93. / 53 Read more »